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RESEARCH ARTICLE
Fibronectin is a serum biomarker for Duchenne
muscular dystrophy
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Purpose: To identify and validate serumbiomarkers for the progression of Duchennemuscular
dystrophy (DMD) using a MS-based bottom-up pipeline.
Experimental design: We used a bottom-up proteomics approach, including a protein concen-
tration equalization step, different proteolytic digestions, andMS detection schemes, to identify
candidate biomarkers in serum samples from control subjects and DMD patients. Fibronectin
was chosen for follow-up based on the differences in peptide spectral counts and sequence cov-
erage observed between the DMD and control groups. Subsequently, fibronectin levels were
determined with ELISA in 68 DMD patients, 38 milder Becker muscular dystrophy patients,
33 patients with other neuromuscular disorders, and 15 age-matched adult and child controls.
Results: There was a significant increase in fibronectin levels in DMD patients compared to
age-matched controls. Fibronectin levels in patients with Becker muscular dystrophy, Bethlem
myopathy, or myasthenia gravis were comparable to control levels. Progressive elevation in
fibronectin levels was observed in longitudinal samples from 22 DMD patients followed up for
a period of 6 months up to 4 years.
Conclusion and clinical relevance: This study suggests that serum fibronectin levels may
constitute a promising biomarker to monitor disease progression in DMD patients.
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1 Introduction
Biomarker discovery efforts have intensified over the past
years, inspired by the utility of biomarkers for diagno-
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sis, classification and staging of diseases, patient stratifi-
cation for individualized therapies, and monitoring thera-
peutic responses [1, 2]. The process from the discovery of
a molecular biomarker to its clinical application can be
subdivided into two main stages. The initial phase, typically
referred to as discovery, aims to produce a list of candidate
biomarkers through various genomic, transcriptomic, and
proteomic technologies. In the next phase, referred to as val-
idation, the correlation of these candidates to the disease is
verified over a large cohort of samples and ends with valida-
tion in a diagnostic or clinical setting [3]. Biomarker analysis
in easily available body fluids, such as blood or urine, is pre-
ferred. These body fluids, even when not directly related to
the etiology of the disease, often reflect the pathophysiological
state of an individual [4, 5].
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Biomarkers are particularly important for monitoring dis-
ease progression and therapeutic efficacy in rare disorders,
where cohort sizes are small and clinical phenotypes can be
highly variable. This is true forDuchennemuscular dystrophy
(DMD), which is a lethal X-linked muscular disease associ-
ated with muscle wasting and weakness due to muscles that
aremore sensitive to damage during contraction [6]. Amilder
form of the disease, Becker muscular dystrophy (BMD), has a
later onset and a much longer survival [7]. Lacking molecular
biomarkers, the 6-min-walk test is a commonly used clinical
outcome measure to assess disease progression in individ-
ual boys and to assess a therapeutic effect in clinical trials
in DMD [8–10]. High CK (creatine kinase) levels are an early
sign of the disease.Unfortunately, CK is not a good biomarker
to monitor disease progression, since CK levels vary largely
from day to day, are influenced by activity, and decrease in
later stages of the disease due to significant muscle loss [11].
There is no cure for DMD and corticosteroids represent
the only palliative treatment able to slow down disease pro-
gression [12]. To evaluate new therapeutic compounds, non-
invasive biomarkers correlating with disease progression are
highly desired, since for most clinical trials invasive muscle
biopsies are required to perform histological assessment and
molecular analyses. Additionally, a single biopsy may not be
representative of the general condition of the muscles. Blood
biomarkers that give a general picture of the pathology, cor-
relate with disease progression, and allow therapeutic mon-
itoring, would therefore be very valuable for future trials in
DMDpatients.We described earliermatrixmetalloproteinase
(MMP)-9 as a biomarker for DMD disease progression [13].
However, it is unlikely that a single biomarker would give suf-
ficient insight in the complex spectrum of pathophysiological
events in a multifaceted disease like DMD. Therefore, unbi-
ased biomarker discovery approaches are invaluable. Mouse
models for DMD have been exploited for serum biomarker
discovery [14,15], but the relevance of the identified biomark-
ers for human patients is yet unclear.
Protein sequencing by MS/MS has evolved into a widely
applied and standardized method for biomarker discovery
[16,17]. The bottom-up approach involves the digestion of pro-
teins by specific enzymes followed by MS/MS-analysis of the
resulting peptides, usually after online separation with LC.
Most fragmentation studies of peptides are based on CID, in
which neutral gasmolecules induce dissociation of the amide
bonds in thepeptide backbone (b/y-fragmentation) [18]. There
is a growing interest in electron-based approaches to frag-
ment peptides in general, and great benefits have been re-
ported for those carrying PTMs [19–21]. The most popular
one is electron transfer dissociation (ETD), inwhich fragmen-
tation is induced after “addition” of an electron to a multiply
charged peptide through a fluoranthene charge carrier [20].
The resulting peptide radical is unstable and undergoes frag-
mentation with preferred peptide backbone dissociation be-
tween the nitrogen and the alpha-carbon (c/z-fragmentation).
Application of two complementary fragmentation methods
may result in improved peptide confidence levels and de-
tection of increased numbers of peptides and numbers of
distinct proteins [22].
Comparative discovery MS-based proteomics pipelines
comparing disease and control samples are powerful tools for
the identification of new disease biomarkers [23]. MS/MS-
based approaches allow for reliable protein identification.
This is of particular importance in biomarker research for
clinical and diagnostic applications, where selected proteins
subsequently need to be analyzed with validated assays across
large patient cohorts. In biomarker discovery studies, it is
also important to quantify relative differences between sam-
ples, for which several protein-labeling approaches are avail-
able [24]. However, label-free approaches are an alternative
to costly labeling techniques and involve a less tedious sam-
ple work-up, allowing measurement of significant changes
within complex mixtures in a single experiment. In label-free
approaches, the spectral count for a protein, that is, the sum
of all MS/MS spectra for a protein, has been shown to be a
reliable semiquantitative estimate of the relative abundance
of a protein [25–27].
The top hit from our semiquantitative biomarker discov-
ery approach, comparing serum samples fromDMD patients
and control individuals, was fibronectin. Fibronectin was fur-
ther validated by targeted immunoassays in larger and lon-
gitudinal DMD cohorts. To address its specificity for DMD,
we studied fibronectin levels in patients affected by other
myopathies.
2 Materials and methods
2.1 Study participants
Blood was taken fromDMD, BMD, Bethlemmyopathy (BM),
myasthenia gravis (MG), and control groups. Three to five
microliters of venous blood was drawn and placed in BD-
Vacutainer (367614) tubes. Blood was allowed to clot at room
temperature for 30 min to 8 h before spinning at 2800 × g at
room temperature for 10 min. Serum supernatant was care-
fully removed, aliquotted, and stored at −80C pending use.
Sixty-eight male patients with a genetic diagnosis of DMD
(mean age 12.5, age range between 2.9 and 31.2 years) were
recruited for this study in the academic hospitals of New-
castle and Leiden. Twenty-two DMD boys were followed up
in a longitudinal study involving blood collection at various
time intervals. Thirty-eight BMD patients older than 18 years
were selected from Newcastle and Leiden (mean age 42.4,
age range between 19 and 67 years). We also included in
the study 13 BM patients (mean age 28.4, age range 0.4–
62.2 years) and 19 MG patients (mean age 31.7, age range
11.3–43.1 years). As part of the study, six adult male volun-
teers (mean age 33.3, age range 29.5–35.2 years), and tenmale
child controls (evaluated for urinary infection by renal isotope
imaging; affected subjects were excluded from our study;
mean age 8.7, age range 6.5–11.1 years) were recruited. None
of the controls had significant medical disorders or systemic
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medication. The study was approved by the local Research
EthicsCommittee prior to commencement. For theMS-based
screens, we created four pools of four samples (adult controls,
child controls, ambulant DMD, and nonambulant DMD).
2.2 MS analysis of serum samples
Mentioned pools of four sampleswere utilized for the bottom-
up proteomics approach (Fig. 1). ProteoMinerTM (Bio-Rad,
Hercules, CA, USA) beads were used to reduce the high dy-
namic range of the serum proteome. A mixture of 50 L
of serum and 100 L of MilliQ water from Millipore (Bed-
ford, MA, USA) was loaded on to 20 L of beads in the
ProteoMiner kit and further instructions from the manufac-
turer’s protocol were followed. The ProteoMiner eluates from
the four different groups were fractionated on aMini-Protean
Tris-Glycine (TGX) 4–20% gradient precast gel (Bio-Rad) for
which a prestained protein ladder 170 – 10 kDa (Fermentas,
Germany) was used. The gel was stained for 1 h with 25 mL
of SimplyBlueTM SafeStain (Invitrogen, USA). Lanes were
cut into ten equidistant pieces. The ten gel pieces from each
group were washed with a solution of 25 mM ammonium
bicarbonate: 50% ACN (mixed 1:1 v/v) and repeated until
the gel pieces were destained. Then, the pieces were alky-
lated with 50 L of 50 mM DTT (Sigma-Aldrich, Steinheim,
Germany) at 56C for 45 min and reduced with 50 L of
50 mM iodoacetamide (Sigma-Aldrich) in the dark for 1 h.
The reduced gel pieces were kept for overnight digestion
with 20 ng/L of trypsin in 25 mM NH4HCO3 (Promega,
USA) or with 12.5 ng/L Lys-N in 50 mM NH4HC03 (U-
Protein Express BV, The Netherlands) in a water bath set to
37C. The peptides were extracted from the gel pieces by addi-
tion of 15 L extraction buffer (50% ACN, 0.1% formic acid)
and agitation for 15 min. The last step was repeated three
times. Each time the supernatant was collected and pooled
and lyophilized. The lyophilized fractions were suspended
in 20 L of 0.1% formic acid (Sigma-Aldrich and separated
using a reverse phase NanoLC-Ultra 2D plus UHPLC (Eksi-
gent, CA, USA), equipped with Eksigent analytical columns
(ChromXP C18, 0.3 mm id× 150 mm, 3 m particle size),
and precolumns from LC Packings (Acclaim Pepmap 300
C18, 300 m id × 55 mm, 5 m particle size). The mobile
phases consisted of (A) 0.05% v/v formic acid in MilliQ water
(Millipore) and (B) 0.05% v/v formic acid, 95% v/v ACN in
MilliQ water (LC-MS grade, Fisher Scientific, USA). Pep-
tide separations were carried out using a 120 min linear
gradient, starting with 96% A and 4% B, and ending with
68% A and 32% B at a flow rate of 4 L/min. The UH-
PLC was coupled to an Amazon ETD ion trap instrument
(BrukerDaltonics). All samples were measured in positive
ion mode. The LC system was controlled by HyStar software
(version 3.4, BrukerDaltonics) with a plugin from the LC-
manufacturer. The ion trap was controlled by EsquireControl
software (version 7.0, BrukerDaltonics). The parameters used
for measurements were capillary voltage 4500 V; plate offset
500 V; dry gas 3.0 L/min; dry temperature 220C; Nebulizer
10 psi. Independentmeasurements forCIDandETDwere ob-
tained from each trypsin or Lys-N digested fraction. Exclusion
limits were automatically placed on previously selected mass-
to-charge ratios for 0.5 min. The ion trap MS/MS datasets
acquired with CID and ETD fragmentation methods were
processed using DataAnalysis software (version 3.3, Bruk-
erDaltonics), that is, find compounds (AutoMS(n)) with de-
convolution options. The peak lists were exported as amascot
generic file (mgf) and searched against theHuman Swissprot
protein sequence database using the Mascot search engine.
The search parameters included carbamidomethylation as a
fixed modification, with enzyme specificity either trypsin or
Lys-N. Mass tolerances were set at 0.5 Da for MS and 1 Da
for MS/MS; three missed cleavage sites were allowed and
number of hits set to auto. For the Mascot search, “ETD
trap” was used as “instrument type” to search ETD spectra
and “ESI trap” to search CID spectra. Methionine oxidation
was allowed as a variable modification. Proteins were assem-
bled on the basis of peptide ion score >30 and probability
p < 0.05. Decoy database option was considered to filter out
false-positive hits. The Mascot search results were exported
as dat files and then converted to pepXML file format us-
ing the MASCOT2XML tool in the Trans Proteomic Pipeline
(TPP) [28]. PeptideProphet and ProteinProphet were used as
a tool for identification and validation [28–31]. Next to the
“standard” protein searches using the SwissProt database,
spectral library searches were performed in which spectra
were compared against a library of previously identified spec-
tra categorized in PeptideAtlas [32]. Spectral library search-
ing, advantageous for matching relatively low quality spec-
tra in comparison to sequence search engines [33], was
performed using the SpectraST tool within the TPP. The
rawMS/MS datasets were converted into mzXML file format
using CompassXport 3.0.4 (BrukerDaltonics). The mzXML
files were searched against a consensus human plasma li-
brary of tryptic digest constructed from the 40 public datasets
from PeptideAtlas. Only CID spectra from tryptic digests
were searched against the human plasma library since no
library is yet available for ETD datasets and Lys-N datasets.
PeptideProphet software (TPP) was used to validate peptide
identifications by calculating probabilities for correct peptide-
to-spectrum matches. In this model deviations between ob-
served masses and calculated masses were evaluated, as well
as search scores, number of enzymatic termini, number of
missed cleavages, and retention times. Peptide identifica-
tions were further validated using iProphet software (TPP).
This algorithm assesses repeated discoveries of the same
peptide ion or the same peptide sequence with a different
charge state or modification, thereby rewarding or penalizing
the peptide-to-spectrummatches.Model parameters includes
the number of sibling peptides, the number of replicate spec-
tra and the number of sibling ions. As a final step in the data
analysis pipeline, protein-level validations were performed
using ProteinProphet software (TPP). Here, protein identi-
fication probabilities were calculated based on the number
C© 2014 The Authors PROTEOMICS – Clinical Applications Published by Wiley-VCH Verlag GmbH & Co. KGaA www.clinical.proteomics-journal.com
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Figure 1. Workflow for DMD
biomarker analysis. Pools of
child control, adult control, am-
bulant DMD, and nonambu-
lant DMD serum samples were
subjected to ProteoMiner treat-
ment, in-gel digestion, and anal-
ysis on an Eksigent UPLC and
HCT ion trap (Bruker Daltonics).
Spectral counts of the identi-
fied proteinswere compared be-
tween the four pools and candi-
date biomarkers for DMD were
validated by ELISA measure-
ments in individual independent
serum samples.
of unique peptides per protein where peptides with multi-
ple siblings are given a higher probability while penalizing
peptides without siblings. A protein inference analysis was
performed to create the simplest list of proteins that can
explain all the peptide observations [28]. Each protein is as-
signed a probability of being present in the sample. Proteins
with probability between 1 and 0.8 were chosen for compar-
ison. The spectral counting approach was used to compare
relative protein abundance in the four different groups. This
was achieved by comparing the number of identified MS/MS
spectra from the same protein in each of the LC-MS/MS
datasets.
2.3 Determination of fibronectin levels in serum
samples
Levels of fibronectin were determined in independent co-
horts using a commercially available ELISA kit (catalog num-
ber ECM300) purchased from Millipore. This kit uses the
competitive enzyme immunoassay technique where the la-
beled antigen competes with the sample antigen for the
binding to the primary antibody. All experiments were car-
ried out in duplicates using the manufacturer’s protocols.
For each individual 2 L of serum were diluted in PBS at
1:10 000 ratio. The unknown concentrationswere determined
from the standard curve by plotting the log of concentra-
tions on the X-axis and the mean of 450 nm absorbance on
the Y-axis.
2.4 Statistical Analysis
Statistical analysis was performed using the Statistical Pack-
age for the Social Sciences (SPSS), version 20 (IBM). For
comparisons between means, a 2-tailed t-test was applied.
Pearson correlation analysis was used to determine the corre-
lation between serum fibronectin levels and clinical parame-
ters like age and corticosteroid therapy. A linear mixedmodel
was used to study the effect of disease progression on serum
fibronectin levels. Individuals were treated as the random
effect and follow-up time as the fixed effect.
3 Results
3.1 MS workflow
Serum samples pooled from adult controls, child controls,
ambulant and nonambulant DMD patients were used to
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screen for DMD candidate biomarkers. A summary of the
biomarker discovery workflow is given in Fig. 1. Each serum
pool was processed with a ProteoMinerTM protein enrich-
ment kit aiming at equalization of the large range in pro-
tein concentrations [34]. Previously, it was shown that by
applying a combinatorial hexapeptide library attached to
ProteoMinerTM beads the large variation in protein con-
centrations was decreased in complex biological samples,
thus resulting in a relative enrichment of medium- and/or
low-abundant proteins [34, 35]. After treatment of the sam-
ples with ProteoMinerTM, the serum pools were fraction-
ated on a 1D SDS gel, as shown in Supporting Information
Fig. 1A. The reproducibility of ProteoMiner is shown in
Supporting Information Fig. 1B. Comparison of the eluates
with the corresponding flow-through fractions shows the re-
moval of the majority of albumin (Supporting Information
Fig. 1A).
3.2 LC-MS/MS identifications
As a next step, each lane was cut into ten equidistant pieces
(shown in Supporting Information Fig. 1). Then, proteins
were reduced and alkylated, and subjected to overnight prote-
olysis with either trypsin or Lys-N, and finally peptides were
extracted. Two replicate gels were used to obtain 80 digest
samples in total, namely ten times four tryptic and ten times
four Lys-N digests of adult controls, child controls, ambu-
lant and nonambulant DMD patients, respectively. All di-
gests were analyzed on a nanoUHPLC CID/ETD ion trap
system and MS/MS peak lists were analyzed and validated
using TPP. CID and ETD fragmentation methods resulted in
approximately 250–300 validated peptide IDs in each sam-
ple group at a false discovery rate of 1% at the peptide
level. An overview of the number of peptide IDs is given in
Fig. 2. The number of tryptic peptides identified was always
higher fromCID spectra.Most identified peptides were in the
mass range of 1000–1500 Da, and second between 1500 and
2000 Da. The number of Lys-N peptide identifications with
a mass higher than 1500 Da, was higher in ETD than in
CID spectra in all samples (Fig. 2). On the other hand, the
smaller Lys-N peptides were well fragmented by CID. There
is clear complementarity of ETD and CID in the nature of the
identified peptides (Supporting Information Table 1).
3.3 Evaluation of confidence of protein
identifications
For validation of the peptide identifications iProphet
probability values were determined. These values were sum-
marized for all four sample pools and are plotted in Sup-
porting Information Fig. 2, for tryptic and Lys-N peptides
separately. In general, a probability value of 0.95 corresponds
to a false discovery rate of 1% [29]. Plots show that the ma-
jority of values are within this confidence level. No differ-
ences were observed between the probability scores of CID
and ETD identified peptides, which is in agreement with a
previous report comparing Mascot scores of CID and ETD
data [36]. ProteinProphet was used to build the simplest list
of proteins sufficient to explain all observed peptides. Subse-
quently, the number of all MS/MS spectra for this list of pro-
teins were determined (spectral counting) and used for semi-
quantitative evaluation of protein abundance in the different
pools.
3.4 Difference in spectral counts
Through trypsin digestion in combination with CID frag-
mentation, fibronectin peptides and protein were confidently
identified in all four groups with high probability scores
(with PeptideProphet probability scores of >0.9 and Protein-
Prophet probability scores of>0.99 for peptides and proteins,
respectively). From the list of quantified proteins, fibronectin
was the only protein with consistent and > threefold dif-
ferences between both control and both DMD groups (Sup-
porting Information Table 2). Moreover, the higher spectral
counts in themore severe, nonambulant over ambulantDMD
patients, suggest that fibronectin levels increase during the
progression of the disease.
3.5 ELISA-based quantification of fibronectin serum
levels
Fibronectin was further validated as a biomarker for DMD by
ELISA measurements in independent DMD sample cohorts
using age-matched controls. In accordancewith theMS-based
findings in the discovery cohort, fibronectin levels in DMD
patients were found elevated compared to child controls, as
shown in Fig. 3A (492± 192 and 86± 23g/mL, respectively,
p < 0.001). There was no significant difference in serum
fibronectin levels between DMD patients from Leiden and
Newcastle. We did not find a significant difference between
ambulant and nonambulant DMD patients. Fibronectin lev-
els were not significantly associated with age (Pearson corre-
lation coefficient 0.119, p = 0.334, Supporting Information
Fig. 3), nor with years on corticosteroid treatment (correlation
coefficient of 0.114, p = 0.354).
3.6 Longitudinal analysis of fibronectin levels in
DMD patients
Longitudinal serum samples were collected from 22 DMD
patients, who were followed up for 6 months to 4 years. The
observed trends in fibronectin levels are plotted in Fig. 4. To
determine whether fibronectin levels increased during pro-
gression of the disease, longitudinal data were analyzed us-
ing a linear mixed model. The levels of fibronectin increased
significantly with the progression of the disease (p < 0.01).
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Figure 2. Number of peptide identifications categorized in tryptic and Lys-N digests, and for different mass ranges. (A) and (B) represent
the peptides from the adult control group (E1 in Supporting Information Fig. 1), (C) and (D) represent the peptides from child control group
(E2 in Supporting Information Fig. 1), (E) and (F) represent the peptides from the DMD ambulant group (E3 in Supporting Information
Fig. 1), and (G) and (H) represent the peptides from DMD nonambulant group (E4 in Supporting Information Fig. 1).
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Clinical Relevance
DMD is a devastating neuromuscular disorder. Non-
invasive tests to evaluate disease progression are
lacking. The only serum biomarker currently used
for early detection of muscular dystrophy is serum
CK, the levels of which are markedly increased in
early stages of DMD. However, serum CK levels de-
crease with the progression of the disease and they
do not correlate with clinically assessed muscle per-
formance. Therefore, they cannot be used for ther-
apeutic monitoring during, for example, clinical tri-
als. The aim of the study was to identify serum pro-
tein biomarkers that correlate with disease progres-
sion andmay show an earlier response to treatments
than functional parameters. From a panel of poten-
tial serum biomarkers identified by MS, fibronectin
was selected and validated as a potential biomarker
correlated with DMD disease progression.
Figure 3. ELISA-based measurements of serum fibronectin lev-
els. (A) Fibronectin levels in DMD patients compared with child
controls. (B) Fibronectin levels in adult BMD patients and adult
controls. The median levels are indicated by the horizontal lines
bisecting the boxes showing the interquartile range. The upper
and lower limit of the bars show the maximum and minimum
values considered. A t-test was used to test for statistically sig-
nificant differences between groups. * indicates significance at
p < 0.001.
Figure 4. Serum fibronectin levels for the longitudinal DMD pa-
tient cohort. The serum fibronectin levels of 22 DMD patients over
2–4 time points (depending on sample availability) are plotted.
The time points are represented as the patient’s age.
There was, however, a downward trend in the two oldest non-
ambulant DMD patients. In contrast, CK levels decreased
significantly with age (p < 0.01, Supporting Information
Fig. 4).
3.7 Measurements in other muscular dystrophies
Evaluation of fibronectin levels in less severely affected BMD
patients was restricted to 38 adult patients. We noted that the
levels in adult controls were significantly higher than in child
controls (p< 0.001). However, there was no significant differ-
ence in serum fibronectin levels between BMD patients and
adult controls (272 ± 205 and 307 ± 59 g/mL, respectively,
Fig. 3B). Likewise, fibronectin levels in BM and MG patients
were not significantly different from controls (117 ± 81, and
170 ± 104 g/mL, for BM and MG, respectively).
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4 Discussion
Exploration of fibronectin as a potential biomarker tomonitor
DMD disease progression was hinted at by protein identifi-
cations and spectral counting of MS/MS data. The TPP anal-
ysis workflow revealed a difference in the number of spectral
counts between the four different analyzed groups (adult con-
trol, child control, DMD ambulant, and DMD nonambulant).
The increased spectral counts in adult versus young controls
and DMD versus controls were confirmed by the absolute
ELISA-based quantifications. The increased spectral counts
in nonambulant versus ambulant DMD patients were not re-
flected by the ELISA experiments, likely due to the pooling of
only a limited number of subjects for the MS-based screen.
Fibronectin levels have been described to be compara-
ble in children and adults and to remain constant from the
age of 1 year onwards [37,38]. Our observations demonstrate
that levels in control children are lower than those in adults.
Therefore, it is important to include age-matched controls.
Fibronectin levels did not correlate significantly with the age
of DMD patients, likely due to relatively large interindivid-
ual variability in such a cross-sectional study. Still, we found
a positive correlation of fibronectin levels with age in the
analysis of longitudinal samples taken at different intervals.
This suggests that fibronectin levels increase as the disease
progresses and would therefore be suitable as biomarker to
monitor disease progression and response to therapy in clin-
ical trials, as long as the baseline levels from the patients
have been evaluated. It will be better suited as a biomarker
for monitoring therapeutic response than CK, since a drop in
CKmay either be due to (undesired) progressive loss of mus-
cle mass [11] or (desired) improvements in muscle integrity.
Fibronectin has been linked to fibrosis, which is one of the
hallmarks of muscular dystrophies and contributing to mus-
cle dysfunction and the lethal phenotype of DMD [39]. Colla-
gen is the most predominant extracellular matrix component
of fibrotic tissue. Several studies showed that excessive de-
position of fibronectin precedes collagen deposition [40, 41].
Moreover, gene expression profiling studies onmuscles from
DMD patients during the early phases of the disease re-
vealed fibronectin gene expression to be upregulated by al-
most twofold [42]. Our studies in longitudinal patient cohorts
also show that serum fibronectin levels are elevated in young
DMD patients with significant increase over time, at least un-
til approximately the age of 15. This warrants further studies
correlating fibrotic content in skeletal or heart muscles with
fibronectin levels in serum, validating serum fibronectin as
a surrogate biomarker for fibrosis. Moreover, more extensive
studies into the correlations of fibronectin levels with func-
tional measures for skeletal or cardiac muscle performance
would be highly informative.
In DMD patients, fibrosis has also been associated with
increased numbers of activated macrophages [43, 44] that se-
crete proteases such as MMPs. Serum levels MMP-9 and its
specific inhibitor tissue inhibitor of metalloproteinase-1 have
been investigated in DMD patients. Serum MMP-9 levels
have been suggested before as a biomarker for monitoring
disease progression in patients with DMD [45]. Fibronectin
acts as one of the substrates of MMP-9. A study by Opde-
nakker et al. [46] suggests that fibronectin inhibits secretion of
proMMP-9 and monocyte migration, whereas its fragmented
form increases secretion. Monocytes contribute to ECM re-
modeling by degrading its proteins via secretion of proteases
such as MMP-9 on the one hand and by depositing ECM pro-
teins such as fibronectin on the other hand. A feedback loop
exists between MMP-9 and fibronectin, as MMP-9 degrades
fibronectin, and binding of fibronectin upregulates the ex-
pression of MMP-9 [46–48]. We could not find a correlation
between the MMP-9 levels and fibronectin levels measured
in the cross-sectional study of 68 DMD patients nor in the
longitudinal study of 22 DMD patients (Spitali, manuscript
in preparation). This may be explained by the presence of the
described feedback mechanisms.
In a study of skin atrophy in mice, fibronectin levels were
found to be increased by corticosteroid therapy [49]. Another
study demonstrated that corticosteroids significantly reduced
peribronchial fibrosis in a mouse model of airway remodel-
ing [50] and a study by Tomic et al. [51] showed that corti-
costeroids reduced lung tissue remodeling by lowering the
levels of fibronectin. In our cross-sectional study of 68 DMD
patients, there was no correlation of fibronectin levels with
the duration of corticosteroid therapy or age. In contrast, the
increase of fibronectin levels with age was significant in the
longitudinal study that included patients on continuous cor-
ticosteroid therapy. To dissect the effect of corticosteroids on
fibronectin levels in DMD, it would be necessary to sample
steroid-naı¨ve patients at baseline and at regular levels after
commencement of corticosteroid therapy.
Fibronectin levels were not elevated in the other patient
cohorts evaluated. These diseases generally have lower (BMD
and BM) or no (MG) muscle fibrosis, supporting the asso-
ciation of fibronectin serum levels with progressive muscle
fibrosis.
Antifibrotic therapies, such as those inhibiting transform-
ing growth factor beta1 [52, 53] or myostatin [54] and anti-
sense oligonucleotide exon skipping [55], are investigated as
a potential treatment approach for DMD. Fibronectin may
constitute a promising molecular biomarker to monitor re-
sponse towards antifibrotic and other DMD therapies that
induce muscle tissue remodeling.
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